1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

England To Get ‘First Ever’ Patient Safety Commissioner Next Year

 
• By Vibha Sharma

The UK government has revealed a number of changes it is making to the health care system in response to a report that found serious lapses regarding the safety of patients who were using certain treatments. 

Image of doctor holding patient's hand to encourage, talking with patient cheering and support.
UK Wants To Improve How Its Health Care System Responds To Patients Concerns • Source: Alamy

England could get its first independent “patient safety commissioner” by early 2022 as part of several new initiatives being rolled out by the government to address the many failings of the UK’s medicines and medical devices safety framework that were highlighted in a scathing report last year.

In its 26 July response to the report, the government said that the new commissioner would have statutory powers to fulfil its core role of ensuring that patients are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By Vibha Sharma

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.

EMA Rejects Treatments For Pediatric Myopia & CTCL

 
• By Vibha Sharma

EU marketing applications for drugs aimed at slowing myopia progression in children and for treating cutaneous T-cell lymphoma have been turned down by the European Medicines Agency.

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’

 
• By Francesca Bruce

Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.